Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07239947
PHASE1

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

Sponsor: Bambusa Therapeutics

View on ClinicalTrials.gov

Summary

This is a Phase 1, randomized, blinded, placebo controlled, single ascending dose (SAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Official title: A Randomized, Blinded, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 in HVs and AD Patient

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

63

Start Date

2025-08-09

Completion Date

2027-03-26

Last Updated

2025-11-20

Healthy Volunteers

Yes

Interventions

DRUG

BBT001

BBT001 will be administered

DRUG

Placebo

Placebo will be administered

Locations (10)

The Second Hospital of Anhui Medical Univesity

Hefei, Anhui, China

The Second Affiliated Hospital of Wannan Medical College

Wuhu, Anhui, China

Peking University People's Hospital

Beijing, Beijing Municipality, China

Dermatology Hospital of Southern Medical University

Guangzhou, Guangdong, China

The Second Xiangya Hospital of Central South University

Changsha, Hunan, China

Wuxi Second People's Hospital

Wuxi, Jiangsu, China

Jiangsu University Affiliated Hospital

Zhenjiang, Jiangsu, China

Jiangxi Provincial Dermatology Hospital

Nanchang, Jiangxi, China

Shandong Provincial Hospital for Skin Diseases

Jinan, Shandong, China

Shanghai Dermatology Hospital

Shanghai, Shanghai Municipality, China